33 results about "Human gut" patented technology

A media supplement for culturing anaerobic bacteria is provided which comprises a filtrate of effluent from a chemostat vessel in which a target bacterial ecosystem has been cultured. Methods of using the supplement for culturing or isolating anaerobic microbial strains or communities, particularly anaerobic bacteria from the human gut, are also provided.

Many diseases with origin in human gut are of unknown causes, so only symptoms are treated. Endoscopic devices leave about 15′ of gut unexplored other than by autopsy. Thus, a substance and microbe simultaneous sample collecting, testing, evaluation, and characterization system has been invented that will provide data for evaluating functions, macro, and micro processes taking place along entire length of the human digestive and intestinal tract from mouth to anus. The entire digestive process including biochemical reactions and microbe roles, and consequences, as pertain to diseases and illnesses can be ascertained through applications of the system, which includes protocols, for collection and preservation of digestion products for external analysis, measurements of many in vivo conditions, and internally processing data and making decisions based upon said processed data, including administration of medications. The system serves clinical diagnostic, treatment and research purposes, and is a dream tool for gastroenterologists.

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR / Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR / Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

This special gut microbe and chemical substance sampling technology, utilizing swallowable capsules, is for purpose of determining roles gut contents play in some 52 of most costly, in lives and dollars, of diseases with their known origin in the human gut. Gut microbes and substances are collected, analyzed, medicinal substances and objects deployed, and special provisions for attracting, capturing and preserving certain strains of microbes, and means for perturbing the gut environment and immune system are all intended to research, discover, and ultimately find both the causes and cures for the most devastating human diseases, and in the process, create gut microbiome profiles.

The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and / or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

Provided are nutritional compositions comprising a combination of a probiotic, dietary butyrate and / or a component for stimulating butyrate production in the human gut. Further disclosed are methods of accelerating tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.

The invention discloses a method for preparing microcapsules by embedding lutein in starch. In this method, a certain concentration of starch milk is firstly heated and expanded for 0.5-2 hours to form expanded starch, and then the solvent containing lutein is added dropwise while keeping warm and stirred, reacted for 0.5-4 hours, cooled, and recrystallized at 4-25°C for 4-2 hours. After 12 hours, centrifuge, wash and dry to obtain lutein microcapsules. The content of lutein in the obtained lutein microcapsules is 2.40-2.54mg / g, and the lutein retention rate can reach 72.1% after the three-week storage stability test, and the release rate can reach 87.2% under the condition of human intestinal fluid, reaching The purpose of targeted intestinal slow-release is more conducive to the absorption and utilization of lutein by the human body. The method is simple, effective and energy-saving for embedding lutein, reduces production cost, enhances the protection of lutein during storage and transportation, has strong stability and good slow-release effect in human intestinal tract.

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR / Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and / or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

A microfluidic device is directed to sustaining a complex microbial community in direct and indirect contact with living human intestinal cells in vitro. The device includes a first microchannel having cultured cells of a human intestinal epithelium and microbiota, the first microchannel further having a first level of oxygen. The device further includes a second microchannel having cultured cells of a vascular endothelium, the second microchannel further having a second level of oxygen. The device also includes a membrane located at an interface region between the first microchannel and the second microchannel, the membrane being composed of an oxygen-permeable material or further having pores via which oxygen flows between the first microchannel and the second microchannel to form a physiologically-relevant oxygen gradient.

Provided are nutritional compositions including a component for stimulating butyrate production in the human gut and / or dietary butyrate. Further disclosed are methods of reducing allergic reaction and promoting tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

This special gut microbe and chemical substance sampling technology, utilizing swallowable capsules, is for purpose of determining roles gut contents play in some 52 of most costly, in lives and dollars, of diseases with their known origin in the human gut. Gut microbes and substances are collected, analyzed, medicinal substances and objects deployed, and special provisions for attracting, capturing and preserving certain strains of microbes, and means for perturbing the gut environment and immune system are all intended to research, discover, and ultimately find both the causes and cures for the most devastating human diseases, and in the process, create gut microbiome profiles.

An in vitro microfluidic intestine on-chip is described herein that mimics the structure and at least one function of specific areas of the gastrointestinal system in vivo. In particular, a multicellular, layered, microfluidic intestinal cell culture, which is some embodiments is derived from patient's enteroids-derived cells, is described comprising L cells, allowing for interactions between L cells and gastrointestinal epithelial cells, endothelial cells and immune cells. This in vitro microfluidic system can be used for modeling inflammatory gastrointestinal autoimmune tissue, e.g., diabetes, obesity, intestinal insufficiency and other inflammatory gastrointestinal disorders. These multicellular-layered microfluidic intestine on-chips further allow for comparisons between types of gastrointestinal tissues, e.g., small intestinal duodenum, small intestinal jejunum, small intestinal ileum, large intestinal colon, etc., and between disease states of gastrointestinal tissue, i.e. healthy, pre-disease and diseased areas. Additionally, these microfluidic gut-on-chips allow identification of cells and cellular derived factors driving disease states and drug testing for reducing inflammation.

The invention relates to the human gut microbiota and its metabolic capabilities. In particular to a method evidencing the functional heterogeneity in the fermentation capabilities of the healthy human gut microbiota. More particularly, the invention provides an in silico method for predicting a response to different dietary fibres based on the analysis and measuring of the fermentation or metabolic capabilities of a subjects gut microbiota as well as a computer software product and an apparatus for predicting a response of a subject to different dietary fibres.

Therapeutic methods for administering gut microbiota and oncolytic viruses to a subject are provided. The gut microbiota serve to pre-condition, the subject's immune system to antitumor responses and augments anticancer activity of the oncolytic vims. Combinations of the gut. microbiota and viruses and uses thereof for treating and preventing cancer are provided. The present disclosure also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome.

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

Therapeutic methods for administering gut microbiota and oncolytic viruses to a subject are provided. The gut microbiota serve to pre-condition, the subject's immune system to antitumor responses andaugments anticancer activity of the oncolytic vims. Combinations of the gut. microbiota and viruses and uses thereof for treating and preventing cancer are provided. The present disclosure also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome.

The present invention relates to the microbiomes of humans and other animals as biomarkers and therapeutic targets for regulation or altering of a microbiome profile associated with states of disease or disease risk, using additive and subtractive therapies aimed at restoring a microbiome profile associated with health, with reduced manifestations of disease, or with reduced disease risk. In particular, the invention provides methods of subtractive therapy using microorganism-specific avian egg yolk-derived immunoglobulins (IgY) in a fashion that titrates, without necessarily eliminating, populations of microorganisms known to be associated with human gut and extraintestinal diseases.

A system and method for reducing the likelihood of colorectal cancer in a human being includes the modification of an individual's gut microbes by employing a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR / Cpf1) system to modify only bacterial genes of bacteria that reside in the human gut that are non-homologous to those encompassed in the human genome, and in particular, to administer a therapeutically effective amount of a bacterial formulation comprising F. prausnitzii that has been modified to produce one of alliin or butyrate.

The present invention addresses the problem of providing a physical activity promoter that includes lactic acid bacteria from the human gut and / or a treated product of such lactic acid bacteria, or a food product composition for promoting physical activity containing same. In order to resolve the foregoing problem, the present inventors administered killed Lactobacillus Gasseri OLL2809 lactic acid bacteria to mice, and thereupon had the novel discovery that in addition to the effect of inhibiting eosinophilic infiltration, the effect of increasing the amount of action was also present. In other words, the present inventors perfected the present invention having discovered that ingesting Lactobacillus Gasseri OLL2809 or a fermented product / treated product thereof promotes physical activity, and specifically increases the amount of activity and also increases muscle mass.

Provided are nutritional compositions comprising a combination of a probiotic, dietary butyrate and / or a component for stimulating butyrate production in the human gut. Further disclosed are methods of accelerating tolerance to cow's milk allergy in a pediatric subject by providing said nutritional compositions to a target subject.

The present invention relates to human gut microbiota and its metabolic capability. The invention particularly relates to a method for proving functional heterogeneity in the aspect of fermentation capacity of healthy human intestinal microbiota. More specifically, the present invention provides a computer simulation (insilo) method for predicting response to different dietary fibers based on analysis and measurement of fermentation or metabolic capability of a subject's intestinal microbiota, as well as a computer software product and apparatus for predicting a subject's response to different dietary fibers.

The invention discloses a lactobacillus salivarius specificity culture medium and application thereof. The culture medium is characterized in that an MRS culture medium is treated as the basis and isimproved, namely, beef extract is removed, the carbon resource is replaced by rhamnose, and antibiotics including vancomycin and streptomycin are added. The culture medium is simple and convenient toprepare, and low in cost; lactobacillus salivarius can be subjected to separating culture, and the viable stains can be counted; the method is reliable in counting result, simple to operate, and low in requirements on experiment people; and meanwhile, the abundance of the lactobacillus salivarius in a sample can be effectively improved during the separating and screening of human gut lactobacillus, and thus the yield of the lactobacillus salivarius is extremely increased. The method is suitably used for preparing and culturing the culture medium for separating lactobacillus salivarius and counting the viable stains.

Therapeutic methods for administering gut microbiota and oncolytic viruses to a subject are provided. The gut microbiota serve to pre-condition, the subject's immune system to antitumor responses and augments anticancer activity of the oncolytic vims. Combinations of the gut. microbiota and viruses and uses thereof for treating and preventing cancer are provided. The present disclosure also provides methods for building elite responder selection platforms through hierarchical clustering analysis of genomic profiles for human gut microbiome.